Erika Mohr-Holland

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study

Gabriella Ferlazzo, Erika Mohr-Holland, Chinmay Laxmeshwar et al. · The Lancet Infectious Diseases · 2018 · 136 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen

Norbert Ndjeka, Kathryn Schnippel, Iqbal Master et al. · European Respiratory Journal · 2018 · 134 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa

Erika Mohr-Holland, Jennifer Hughes, Anja Reuter et al. · European Respiratory Journal · 2018 · 45 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Six-Month Response to Delamanid Treatment in MDR TB Patients

Cathy Hewison, Gabriella Ferlazzo, Zaza Avaliani et al. · Emerging infectious diseases · 2017 · 43 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

How COVID-19 could benefit tuberculosis and HIV services in South Africa

Claire Keene, Erika Mohr-Holland, Tali Cassidy et al. · The Lancet Respiratory Medicine · 2020 · 34 citations · Full text

Public Health, Health Policy, Infectious Diseases +15